Alzheimer's Blood Tests: Track Changes Over Time

Recent research emphasizes that tracking shifts in Alzheimer's-linked protein biomarkers over time provides a more accurate picture than relying on a single blood test. Studies presented this month revealed that conditions like obesity can dilute crucial protein signals, affecting test reliability. Similarly, impaired kidney function can confound results, particularly for biomarkers indicating nerve damage.

Despite these challenges, technological advancements continue to accelerate Alzheimer's detection. The FDA has cleared two blood tests designed to detect Alzheimer's-related biomarkers. One test helps rule out amyloid buildup as the cause of symptoms, while another, intended for specialists, indicates a higher likelihood of these proteins being present in the brain.

Scientists are working to refine these tests for widespread diagnostic use. The ultimate goal is to identify individuals with Alzheimer's disease before dementia develops, enabling earlier treatment to potentially prevent cognitive decline. Tracking biomarker levels over time, rather than at a single point, is crucial for a comprehensive understanding of disease progression.